For your practice

Grifols is committed to partnering with healthcare providers, providing the alpha-1 healthcare community with the resources needed to make a difference in patients' lives.

Order FREE Grifols AlphaKit™ test kits now >
We've made it simple for you to receive FREE Grifols AlphaKit test kits.

Download, complete, and fax the enrollment form >

  • PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) is ONLY available through the PROLASTIN DIRECT program
  • It takes one form to start your patients on PROLASTIN-C LIQUID and connect them to the comprehensive personalized support of the PROLASTIN DIRECT program
  • Call PROLASTIN DIRECT at 1-800-305-7881 with questions

Annotated enrollment form

  • Field-by-field tips to avoid potential errors and ensure successful submission of your enrollment form

Request a representative >

Learn more from a Grifols alpha-1 specialty representative in your area.

Downloadable Alpha-1 Foundation Resources

The following tools from the Alpha-1 Foundation help people with alpha-1 better understand and manage their condition.


Video resources for HCPs and patients

Learn more about alpha-1.
Watch the MOA video>

Learn more about the comprehensive, personalized alpha-1 support for patients and physicians and their practices, available ONLY through the PROLASTIN DIRECT program.
View the full PROLASTIN DIRECT Story>

Partners in patient care

AlphaNet >

Alpha-1 Foundation >

You will need Adobe® Reader® installed on your computer to view PDFs. You can download a copy of Adobe Reader by clicking the link below.

Get Adobe Reader

Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.

Have your patients seen the PROLASTIN DIRECT Story?

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


  1. Data on file, PROLASTIN DIRECT program.